2-propynyl adenosine analogs with modified 5′-ribose...

Details 2-propynyl adenosine analogs with modified 5′-ribose... 2-propynyl adenosine analogs with modified 5′-ribose...

2005-08-02

2009-10-20

McIntosh, III, Traviss C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S045000, C536S027300, C536S027600, C536S027620, C536S027630, C536S027800

Reexamination Certificate

active

07605143

ABSTRACT:
The invention provides compounds having the following general formula (I):wherein X, R1, R2, R7and Z are as described herein.

REFERENCES:
patent: 3892777 (1975-07-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4242345 (1980-12-01), Brenner et al.
patent: 4665074 (1987-05-01), Amschler
patent: 4824660 (1989-04-01), Angello et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5364862 (1994-11-01), Spada et al.
patent: 5561134 (1996-10-01), Spada et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593973 (1997-01-01), Carter
patent: 5593975 (1997-01-01), Cristalli
patent: 5593976 (1997-01-01), Mongelli et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5731296 (1998-03-01), Sollevi
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5776940 (1998-07-01), Daluge et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
patent: 5998386 (1999-12-01), Feldman
patent: 6004945 (1999-12-01), Fukunaga
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6020321 (2000-02-01), Cronstein et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117878 (2000-09-01), Linden et al.
patent: 6232297 (2001-05-01), Linden et al.
patent: 6303619 (2001-10-01), Linden et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6339072 (2002-01-01), Martin et al.
patent: 6350735 (2002-02-01), Monaghan
patent: 6387889 (2002-05-01), Endo et al.
patent: 6407076 (2002-06-01), Box et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6525032 (2003-02-01), Mantrell et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6624158 (2003-09-01), Mantell et al.
patent: 6670334 (2003-12-01), Linden
patent: 6936596 (2005-08-01), Konno et al.
patent: 7214665 (2007-05-01), Linden et al.
patent: 7378400 (2008-05-01), Rieger et al.
patent: 7427606 (2008-09-01), Linden et al.
patent: 2001/0027185 (2001-10-01), Linden et al.
patent: 2002/0032168 (2002-03-01), Mantrell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: 2002/0072597 (2002-06-01), Mantell et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0162742 (2003-08-01), Linden et al.
patent: 2003/0186926 (2003-10-01), Linden et al.
patent: 2005/0182018 (2005-08-01), Linden et al.
patent: 2005/0282831 (2005-12-01), Beauglehole et al.
patent: 2006/0040889 (2006-02-01), Rieger et al.
patent: 2006/0217343 (2006-09-01), Rieger et al.
patent: 2007/0232559 (2007-10-01), Linden et al.
patent: 2008/0009460 (2008-01-01), Linden et al.
patent: 2008/0027022 (2008-01-01), Linden et al.
patent: 0488336 (1995-05-01), None
patent: 0700908 (1996-03-01), None
patent: 1194440 (2002-04-01), None
patent: 1150991 (2004-04-01), None
patent: 174074 (1979-10-01), None
patent: WO-93/22328 (1993-11-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-96/04280 (1996-02-01), None
patent: WO-98/47509 (1998-10-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-99/34804 (1999-07-01), None
patent: WO-99/38877 (1999-08-01), None
patent: WO-99/41267 (1999-08-01), None
patent: WO-99/62518 (1999-12-01), None
patent: WO-99/63938 (1999-12-01), None
patent: WO-99/67263 (1999-12-01), None
patent: WO-99/67264 (1999-12-01), None
patent: WO-99/67265 (1999-12-01), None
patent: WO-99/67266 (1999-12-01), None
patent: WO-00/44763 (2000-01-01), None
patent: WO-00/23457 (2000-04-01), None
patent: WO-00/72799 (2000-12-01), None
patent: WO-00/78774 (2000-12-01), None
patent: WO-00/78777 (2000-12-01), None
patent: WO-01/94368 (2001-12-01), None
patent: WO-02/09701 (2002-02-01), None
patent: WO-02/22630 (2002-03-01), None
patent: WO-02/096462 (2002-12-01), None
patent: WO-03014137 (2003-01-01), None
patent: WO-03/014137 (2003-02-01), None
patent: WO-03/029264 (2003-04-01), None
patent: WO-03/086408 (2003-10-01), None
patent: WO-2005/097140 (2005-10-01), None
patent: WO-2006/015357 (2006-02-01), None
patent: WO-2006/023272 (2006-03-01), None
patent: WO-2006/028618 (2006-03-01), None
patent: WO-2007092936 (2007-08-01), None
patent: WO-2007092936 (2007-08-01), None
The Merck Manual of Diagnosis and Therapy, Beers, M.A., et al. (eds.), Merck and Company,(Jan. 1999), 924-925.
Taber's Cyclopedic Medical Dictionary, 19th Edition, Venes, et al. (eds.), F.A. Davis, Philadelphia,(2001), 960-961.
International Search Report for corresponding PCT Application No. PCT/US2005/027479 (Sep. 6, 2006), 6 pgs.
Abiru, T., et al., “Nucleosides and Nucleotides. 107. 2-(Cycloalkylalkynyl)adenosines: Adenosine A1Receptor Agonists With Potent Antihypertensive Effects”,Journal of Medicinal Chemistry, 35(12), (1992), 2253-2260.
Adah, S. A., “Synthesis of Complex Ethynyladenosines Using Organic Triflic Enolates in Palladium-Catalyzed Reactions: Potential Agonists for the Adenosine A2Receptor”,Tetrahedron, 53, (1997), 6747-6754.
Ali, H., et al., “Methylxanthines Block Antigen-induced Responses in RBL-2H3 Cells Independently of Adenosine Receptors or Cyclic AMP: Evidence for Inhibition of Antigen Binding to IgE”,Journal of Pharmacology and Experimental Therapeutics, 258, (1991), 954-962.
Andersson, P., et al., “Anti-anaphylactic and Anti-inflammatory Effects of Xanthines in the Lung”,Curr. Clin. Pract. Ser., (1985), 187-192.
Baraldi, P. G., et al., “Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5′-N-ethyluronamide as A1and A3Adenosine Receptor Agonists”,Journal of Medicinal Chemistry, 41(17), (1998), 3174-3185.
Berkich, D. A., et al., “Evidence of Regulated Coupling of A1Adenosine Receptors by Phosphorylation in Zucker Rats.”,American Journal of Physiology, 268(4), (1995), E693-E704.
Bhattacharya, S., et al., “Effects of Long-Term Treatment With the Allosteric Enhancer, PD81,723, on Chinese Hamster Ovary Cells Expressing Recombitant Human A1Adenosine Receptors”,Molecular Pharmacology, 50(1), (1996), 104-111.
Bhattacharya, S., et al., “The Allosteric Enhancer, PD 81,723, Stabilizes Human A1Adenosine Receptor Coupling to G Proteins”,Biochimica et Biophysica Acta, 1265(1), (1995), 15-21.
Bridges, A. J., et al., “N6-[2-(3,5-Dimethoxyphenyl)-2-(2-Methylphenyl)-Ethyl]Adenosine and Its Uronamide Derivatives. Novel Adenosine Agonists With Both High Affinity and High Selectivity for the Adenosine A2Receptor”,Journal of Medicinal Chemistry, 31(7), (1988), 1282-1285.
Bruns, R. F., “Adenosine Receptors—Roles and Pharmacology”,Biological Actions of Extracellular ATP, 603, Annals of the New York Academy of Sciences, (1990), 211-226.
Bruns, R. F., et al., “Characterization of the A2Adenosine Receptor Labeled by [3H]NECA in Rat Striatal Membranes”,Molecular Pharmacology, 29, (1986), 331-346.
Buster, B., et al., “The Effect of Adenosine Receptor Agonists on Neutrophil Pleocytosis and Blood-Brain Barrier Pathophysiology in Experimental Bacterial Meningitis”,Abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 37, Abstract No. B-72,(1997), p. 39.
Cam

Affiliated with

Also associated with

Rating

2-propynyl adenosine analogs with modified 5′-ribose... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-propynyl adenosine analogs with modified 5′-ribose..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-propynyl adenosine analogs with modified 5′-ribose... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4111931